Date: 6 February 2019 **Sydney, Australia**

ASX: NOX

Noxopharm Limited

ABN 50 608 966 123

Registered Office and Operational Office:
Suite 3, Level 4
828 Pacific Highway
Gordon NSW 2072
Australia

ASX Limited
20 Bridge Street
SYDNEY NSW 2000

FNN INTERVIEW WITH NOX CHIEF MEDICAL OFFICER ON INTERIM DATA

SYDNEY, February 6, 2019, Noxopharm (ASX: NOX) presents a Finance News Network (FNN) interview with its Chief Medical Officer, Dr Greg van Wyk, following the release of interim data for its DARRT-1 clinical trial in late-stage prostate cancer.

The interview: https://www.finnewsnetwork.com.au/MediaCenter/MediaCenterMobile.aspx?Site=FNN1460 can also be found on the Noxopharm website : www.noxopharm.com

---

About Veyonda®

Veyonda® (previously known as NOX66) is an innovative dosage formulation of the experimental anti-cancer drug, idronoxil, developed specifically to preserve the anti-cancer activity of idronoxil in the body and to enhance its drug-like behaviour. Idronoxil inhibits the oncogene, Ecto-NOX disulfide-thiol exchanger type 2, leading to inhibition of the key secondary pro-survival messenger, sphingosine-1-phosphate. This enhances the DNA-damaging effects of radiotherapy and cytotoxic chemotherapy, as well as activating the body's innate immune system.

About DARRT

The Company's DARRT (Direct and Abscopal Response to Radiotherapy) Program is testing the ability of Veyonda® to increase tumour response to palliative dosages of radiotherapy. The DARRT treatment regimen entails a 5-day course of radiotherapy (20-30 Gy) in 5 fractionated dosages targeting a single tumour, and the Veyonda® administered daily for up to 3 weeks. The rationale of DARRT is to combine the radio-enhancing properties of Veyonda® that stem from its inhibition of sphingosine-1-phosphate pro-survival functions, combined with its ability to stimulate the body's first line immune defence cells against cancer. The clinical outcome being sought is greater shrinkage of irradiated tumours and shrinkage of all non-irradiated tumours (abscopal response). The DARRT treatment regimen is being tested initially in prostate cancer, but in due course is to be extended into other forms of solid cancer that the Company believes will assist the Veyonda® marketing approval process.

About DARRT-1

DARRT-1 is a Phase 1b 24-subject study being conducted in Georgia and Australia. The study is in 2 stages, each of 12 subjects. Stage 1 is dose-finding entailing 3 cohorts of 4 subjects receiving 400 mg, 800 mg and 1200 mg Veyonda® respectively. In Stage 2, the 12 subjects are receiving the 1200 mg Veyonda® dose. The subjects are being assessed clinically at 6-, 12- and 24- weeks.

About Noxopharm

Noxopharm is a clinical-stage Australian drug development company with offices in Sydney, New York and Hong Kong. The Company has a primary focus on the development of drugs based on a phenolic chemical structure, with Veyonda® the first pipeline product. The pipeline includes a number of other drug candidates for both oncology (within NOX) and non-oncology indications (in subsidiary company, Nyrada Inc).

Investor & Corporate Enquiries:
Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:
David Franks
T: +61 2 9299 9690
E: David.Franks@automicgroup.com.au

Media Contact:
Allison Blum, Ph.D.
LifeSci Public Relations
T: +1 516 655 0842
E: allison@lifescipublicrelations.com

www.noxopharm.com

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.